Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Thursday announced a collaboration with Ambrx Inc., a clinical stage biopharmaceutical company, for the discovery and development of novel antibody drug conjugates or ADCs.
ADCs allow for the targeted delivery of drugs to the focus tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.
In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation.
Ambrx will receive an upfront payment of $15 million from Astellas, as well as up to $285 million in potential research, development, regulatory and sales-based milestones for an undisclosed number of targets for ADCs in oncology.
A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual successful commercialization of products developed as a result of this partnership, Astellas said.
On its part, Astellas will receive worldwide rights to develop and commercialize ADCs for oncology. Additional terms of the collaboration were not disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.